Tag Archives: access-denied

Cancer therapy using specialized apheresis holds great promise

“What we know now about ECP is that it is able to function in more than one way,” said Ratcliffe. “It can immunotolerize in the autoreactive setting, and immunize against, in a situation such as lymphoma. This enigma poses tremendous opportunity for future basic science investigation in immunology where cancer applications in bone marrow transplantation and lymphoma will benefit from novel therapeutics.” Currently, ECP is used to treat cancer patients who have cutaneous T-cell lymphoma or in patients with Graft versus Host disease after transplantation. There are many questions about how the therapy works and the best schedules for treating patients…

New targeted drugs could treat drug-resistant skin cancer

Existing drugs target faulty versions of a protein called BRAF which drives about half of all melanomas, but while initially very effective, the cancers almost always become resistant to treatment within a year. The new drugs — called panRAF inhibitors — could be effective in patients with melanoma who have developed resistance to BRAF inhibitors…

Early trial of new drug shows promise for patients with metastatic triple-negative breast cancer — ScienceDaily

The multi-center, non-randomized trial was designed to evaluate the safety, tolerability and antitumor activity of bi-weekly infusions of pembrolizumab (MK-3475, marketed as Keytruda�). The researchers enrolled 27 patients, aged 29 to 72 years, who had metastatic triple-negative breast cancer that either relapsed after treatment for early stage disease or progressed on therapy for advanced disease…

Measuring the Malignancy of Prostate Cancer — ScienceDaily

When cancer is diagnosed, the grade of its malignancy is a central concern for both patients and their physicians. This value is used to determine how intensively and how radically the cancer must be treated. Particularly in the case of prostate cancer, the disease can take widely varying courses in different patients…

First gene associated with familial glioma identified

“It is widely thought amongst the clinical community that there is no association between family history and development of glioma. Because we know very little about the contributing genetic factors, when cases occur in two or more family members, it is viewed as coincidental,” said Dr…

Cancer therapy shows promise for nuclear medicine treatment

Targeted therapy with radiopharmaceuticals–radioactive compounds used in nuclear medicine for diagnosis or treatment–has great potential for the treatment of cancer, especially for cancer cells that have migrated from primary tumors to lymph nodes and secondary organs such as bone marrow. These disseminated tumor cells can be difficult to treat with a single targeting agent because there are dramatic differences in the number of targetable receptors on each cell. …

Immunotherapy achieves breakthrough result in patients with Hodgkin lymphoma

The results provide some of the most dramatic evidence to date of the potential of therapies that increase the ability of the immune system to kill cancer cells. While clinical trials of such immunotherapies in other cancers have shown them to be highly effective in a subgroup of patients, the new study stands out because nearly all patients benefited from the treatment…

Boosting length of breastfeeding could save NHS more than �40 million every year

The numbers add up to a strong economic case to invest in services to support mums to carry on breastfeeding, they conclude. In common with many other high income countries, breastfeeding rates in the UK are low, and to find out if boosting these could cut healthcare costs by improving mother and child health, the researchers focused on five priority diseases…